The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
DKN-01 plus bevacizumab and chemotherapy as second-line (2L) investigational therapy in advanced microsatellite stable (MSS) colorectal adenocarcinoma (CRC): DeFianCe trial.
 
Meredith Pelster
Honoraria - Castle Biosciences (I)
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst)
Research Funding - 1200 Pharma (Inst); Actuate Therapeutics (Inst); Agenus (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); BeiGene (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Codiak Biosciences (Inst); Compass Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Elevation Oncology (Inst); Exelixis (Inst); Gilead Sciences (Inst); HiberCell (Inst); Immune-Onc Therapeutics (Inst); Leap Therapeutics (Inst); Novartis (Inst); OncXerna Therapeutics (Inst); Panbela Therapeutics (Inst); Revolution Medicines (Inst); SQZ Biotechnology (Inst); Surface Oncology (Inst); Tachyon Therapeutics (Inst); Translational Genomics Research Institute (Inst); TransThera Sciences (Nanjing), Inc. (Inst); ZielBio (Inst)
 
John H Strickler
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; Beigene; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Inivata; Janssen Oncology; Lilly; Natera (Inst); Pfizer; Roche/Genentech; Seagen; Silverback Therapeutics; Taiho Oncology; Takeda; Viatris
Research Funding - A*STAR (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene; Curegenix (Inst); Daiichi Sankyo/Lilly; Erasca, Inc (Inst); Leap Therapeutics (Inst); Lilly (Inst); Nektar (Inst); Roche/Genentech (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Seagen
 
Cynthia A. Sirard
Employment - Leap Therapeutics
Leadership - Leap Therapeutics
Stock and Other Ownership Interests - Leap Therapeutics
Patents, Royalties, Other Intellectual Property - Pending patent application;Application No. 62/260,959
Travel, Accommodations, Expenses - Leap Therapeutics
 
Jason Baum
Employment - Intercept Pharmaceuticals (I); Leap Therapeutics
Leadership - Leap Therapeutics
Stock and Other Ownership Interests - Intercept Pharmaceuticals (I); Leap Therapeutics
Consulting or Advisory Role - Nuvalent, Inc.
 
Mike Haas
Employment - Leap Therapeutics; Leap Therapeutics
Stock and Other Ownership Interests - Leap Therapeutics
Research Funding - Leap Therapeutics
 
Craig E. Devoe
Honoraria - Vivacitas Oncology
Consulting or Advisory Role - Pfizer
 
Liliana Bustamante
Speakers' Bureau - Amgen
 
Jeffrey Alan Bubis
Honoraria - Blueprint Medicines; Cellectar; Novartis; Oncohost
Speakers' Bureau - AstraZeneca
 
Mark Sanders Womack
No Relationships to Disclose
 
Ki Y. Chung
Research Funding - epizyme (Inst); MedImmune (Inst)
 
Joshua P. Raff
Stock and Other Ownership Interests - Genentech
 
Zev A. Wainberg
Consulting or Advisory Role - Alligator Bioscience; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Ipsen; Lilly; Merck; Merck KGaA; Novartis; Pfizer; PureTech; Seagen
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Lilly; Merck